Equities researchers at Rodman & Renshaw began coverage on shares of CytoDyn Inc. (OTCMKTS:CYDY) in a research note issued to investors on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Shares of CytoDyn (OTCMKTS:CYDY) opened at 0.67 on Thursday. The firm’s market capitalization is $83.44 million. The company has a 50-day moving average of $0.89 and a 200-day moving average of $1.04. CytoDyn has a 52 week low of $0.63 and a 52 week high of $1.57.

CytoDyn Company Profile

CytoDyn Inc is a biotechnology company focused on discovering and developing a class of therapeutic monoclonal antibodies to treats Human Immunodeficiency Virus (HIV) infection. Its lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors. These therapies potentially block HIV from entering into and infecting certain cells.

Receive News & Stock Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related stocks with our FREE daily email newsletter.